Improvements in throat function and qualities of sore throat from locally applied flurbiprofen 8.75 mg in spray or lozenge format: findings from a randomized trial of patients with upper respiratory tract infection in the Russian Federation.

Objective: To assess the speed of relief provided by flurbiprofen 8.75 mg spray and lozenge and their effect on many of the different qualities and characteristics of throat pain and discomfort, and the many articulations of the broad term "sore throat" (ST).

Patients And Methods: Four hundred and forty adults with recent-onset, moderate-to-severe ST due to upper respiratory tract infection (URTI) were randomized to a single dose of either flurbiprofen 8.

Efficacy of flurbiprofen 8.75 mg delivered as a spray or lozenge in patients with sore throat due to upper respiratory tract infection: a randomized, non-inferiority trial in the Russian Federation.

Objective: To assess the efficacy of flurbiprofen 8.75 mg delivered as a spray or lozenge in patients with sore throat due to upper respiratory tract infection (URTI).

Materials And Methods: This multicenter, double-blind, double-dummy, non-inferiority study randomized 440 adults with recent-onset, moderate-to-severe sore throat due to URTI to a single dose of either flurbiprofen 8.

[Integral assessment of endogenous intoxication in patients with phlegmons of maxillofacial area].

The study assessed the correlation of red blood cells structural and functional disorders as a result of tissue metabolism changes and accumulation of final and intermediate metabolic products in association with microbial toxins, as well as changes of plasma general antioxidation capacities with clinical manifestations and degree of endogenous intoxication syndrome in patients with widespread phlegmons of maxillofacial area. The red blood cell structure served as an indicator of all biological membranes condition. The correction of red blood cells structure was achieved by administration of membranoprotective antioxidants.

[Use of data of expected duration of treatment and estimation of severity level for selection of rational therapy in patients with acute inflammatory diseases of maxillofacial region].

There were examined 52 patients with odontogenic phlegmons of maxillofacial area. Patients are distributed on 3 groups on severity level and to expected duration diseases. 18 patients of the basic group received in complex treatment 2.